Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H17F3N4O2S2 |
InChIKeyXPPKZMFJCSEUSX-UHFFFAOYSA-N |
CAS Registry2031177-48-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 01 Jun 2017 | |
Neoplasms | Preclinical | CN | 01 Jun 2017 |